

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Matrix metalloproteinase 2 inhibitor (MMP2 inhibitor)	<p>An SAR study identified <i>cis</i>-2-aminocarbamoylphosphonic acid (<i>cis</i>-ACCP) as an MMP2 inhibitor that could be useful for treating cancer. In a murine model of melanoma, 50 mg/kg of once-daily oral <i>cis</i>-ACCP reduced tumor growth by about 60% and reduced metastasis formation by about 90% compared with untreated controls. Next steps could include additional preclinical testing of <i>cis</i>-ACCP and its analogs.</p> <p>No fewer than nine companies have MMP inhibitors for multiple indications in developmental stages ranging from preclinical to marketed.</p>	Patent application filed; unlicensed	<p>Hoffman, A. <i>et al.</i> <i>J. Med. Chem.</i>; published online Feb. 8, 2008; doi:10.1021/jm701087n</p> <p>Contact: Reuven Reich, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel e-mail: reich@cc.huji.ac.il</p> <p>Contact: Eli Breuer, same affiliation as above e-mail: eli.breuer@huji.ac.il</p> <p>Contact: Amnon Hoffman, same affiliation as above e-mail: amnonh@ekmd.huji.ac.il</p>